

Field Name	Field Description
Prior Authorization Group Description	Brineura (cerliponase alfa)
Drugs	Brineura (cerliponase alfa)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), and the Drug Package Insert, and/or per the National Comprehensive Cancer Network (NCCN)
Exclusion Criteria	N/A
Required Medical Information	See “other criteria”
Age Restrictions	According to package insert Member must be 3 years of age or older
Prescriber Restrictions	Prescriber must be a neurologist
Coverage Duration	If the criteria are met, the request will be approved for 12 months.
Other Criteria	**Drug is being requested through the member’s medical benefit** <u>Initial Authorization:</u> - Documentation of confirmed diagnosis of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) with one of the following: - Lab results demonstrating deficient TPP1 enzyme activity - Identification of causative mutations in the TPP1/CLN2 gene - Documentation of baseline CLN2 Clinical Rating Scale motor +language score. Baseline CLN2 score must be > 0. - Medication is prescribed at an FDA approved dose <u>Re-authorization:</u> - Documentation of CLN2 Clinical Rating Scale motor +language score has remained > 0 - Medication is prescribed at an FDA approved dose Medical Director/clinical reviewer must override criteria when, in his/her professional judgment, the requested item is medically necessary.
Revision/Review Date: 7/2025	4